Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Fijnheer

Showing results (101-110 of 106) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 106 results.
Circulation|August 27, 2023
Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled TrialLinda P T Joosten, Sander van Doorn, Peter M van de Ven, et al.
Blood|May 2, 2020
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpuraElien Roose, An-Sofie Schelpe, Edwige Tellier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)Pieternella Johanna Lugtenburg, Peter de Nully Brown, Bronno van der Holt, et al.
Haematologica|April 16, 2026
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL studyMarie José Kersten, Martin Dreyling, Kim M Linton, et al.
Blood Advances|December 9, 2021
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trialAnita W Rijneveld, Bronno van der Holt, Okke de Weerdt, et al.
Blood Advances|April 18, 2025
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOPMarcel Nijland, Djamila E Issa, Johanna A A Bult, et al.
Pageof 11

Showing results (101-110 of 106) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
Circulation|August 27, 2023
Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled TrialLinda P T Joosten, Sander van Doorn, Peter M van de Ven, et al.
Blood|May 2, 2020
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpuraElien Roose, An-Sofie Schelpe, Edwige Tellier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)Pieternella Johanna Lugtenburg, Peter de Nully Brown, Bronno van der Holt, et al.
Haematologica|April 16, 2026
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL studyMarie José Kersten, Martin Dreyling, Kim M Linton, et al.
Blood Advances|December 9, 2021
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trialAnita W Rijneveld, Bronno van der Holt, Okke de Weerdt, et al.
Blood Advances|April 18, 2025
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOPMarcel Nijland, Djamila E Issa, Johanna A A Bult, et al.
Pageof 11